Case Number 112024 - Preventing the Induction of Fatty Acid Oxidation in Response to S6K1 Inactivation

Contact: Michael Hansen
Email: hansenmh@ucmail.uc.edu
Phone: 513-558-5621

Description:  Dr. David Plas and his lab have identified a new method that enhances cancer cell cytotoxicity when used in combination with Rapamycin.

Although Rapamycin suppresses glycolysis in cancer cells, the cytotoxic benefit of Rapamycin is unexpectedly low in many cancers. Agents that inhibit fatty acid oxidation in tumor cells can compensate for this shortcoming by blocking a key metabolic pathway that cancer cells use to survive during Rapamycin therapy.

A provisional patent is pending.

You can learn more in this article: S6K1 determines the metabolic requirements for BCR-ABL survival and this summary: Preventing the Induction of Fatty Acid Oxidation in Response to S6K1 Inactivation